About Natera

About Natera

Natera is a rapidly-growing diagnostics company with proprietary bioinformatics and molecular technology for analyzing DNA. Natera’s complex technology has been proven clinically and commercially in the prenatal testing space and the Company is actively researching its applications in the liquid biopsy space for developing products with oncology applications.

Since 2009, Natera has launched seven molecular diagnostic tests, many of which are available through major health plans accounting for more than 140 million covered lives in the United States. The Company’s own robust laboratory processes thousands of genetic tests per month.

Natera’s goal is to transform the way people – both providers and patients – respond to and manage genetic diseases.

Learn More About Natera

Stock Information

NTRA (Common Stock)
ExchangeNASDAQ CM (US Dollar)
Price$11.86
Change (%) Stock is Up 0.12 (1.02%)
Volume94,179
Data as of 12/02/16 4:00 p.m. ET
Minimum 15 minute delay
Refresh quote
Stock chart for: NTRA.O.  Currently trading at $11.86 with a 52 week high of $13.80 and a 52 week low of $6.52.

Recent News

The Centers For Medicare And Medicaid Services Establishes 2017 Pricing For Aneuploidy And Microdeletion Testing - 12/01/16
SAN CARLOS, Calif., Dec. 1, 2016 /PRNewswire/ -- Natera (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA announced today that the Centers for Medicare & Medicaid Services (CMS) released final ... More»
Natera to Present at the 28th Annual Piper Jaffray Health Conference - 11/22/16
SAN CARLOS, Calif., Nov. 22, 2016 /PRNewswire/ -- Natera (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today announced that it will present at the 28th Annual Piper Jaffray Health Conference i... More»
Natera Reports Third Quarter 2016 Financial Results - 11/09/16
SAN CARLOS, Calif., Nov. 9, 2016 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today reported financial results for the third quarter ended September 30, 2016 and ... More»
Natera Inc. Announces Third Quarter Earnings Conference Call - 11/02/16
SAN CARLOS, Calif., Nov. 2, 2016 /PRNewswire/ -- Natera (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today announced that it will release results for its third quarter ended September 30, 201... More»
Natera Announces Two Poster Presentations on Triploidy and Duchenne Muscular Dystrophy to be Featured at the 2016 American Society for Reproductive Medicine (ASRM) Conference - 10/13/16
SAN CARLOS, Calif., Oct. 13, 2016 /PRNewswire/ --Natera (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today announced that it will present data from Horizon™ carrier screen and Spectrum® pre-i... More»

Upcoming Events

Webcast
Natera Inc at the 28th Annual Piper Jaffray Health Conference (Replay)
11/29/16 at 4:00 p.m. ET
Natera Inc at the 28th Annual Piper Jaffray Health Conference
Tuesday, November 29, 2016 4:00 p.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
There are currently no events scheduled.

Recent Presentations

There are currently no items available.

The information provided in this area of the website is maintained by a third-party service. Natera is not responsible for the accuracy, currency or completeness of the information contained herein.
Data provided by Nasdaq. Minimum 15 minutes delayed.
Shareholder Tools